News

A new cumulative analysis from the PIONEER trial provides encouraging long-term data on avapritinib for indolent SM.

Patients who test negative for the KIT D816V mutation may need further testing for clonal mast cell diseases such as SM, a study found.

Symptom diary is typically excellent at inducing memory recall in tracking disease evolution in SM.

HT-KIT, a new treatment for SM and other cancers, has shown promising results in early laboratory studies.

Outcomes among patients with mast cell leukemia remain relatively poor.

A case report was recently published describing a man with systemic mastocytosis and a previously unknown KIT mutation.

Major progress has been made in the treatment of SM, but patients with the most aggressive forms of the disease still need better options.

Systemic mastocytosis with an associated hematologic neoplasm (SM-AHN) appears to have a higher mutational burden than isolated SM.

People with mastocytosis may have an elevated risk of melanoma and basal cell carcinoma compared to the general population.

A new review underscores how genetic research is transforming the diagnosis and management of systemic mastocytosis.